T. Rowe Price Associates, Inc. 13D and 13G filings for Global Blood Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 2:34 pm Sale | 2021-12-31 | 13G | Global Blood Therapeutics, Inc. GBT | T. Rowe Price Associates, Inc. | 3,260,685 5.000% | -802,438 (-19.75%) | Filing |
| 2021-02-16 12:23 pm Sale | 2020-12-31 | 13G | Global Blood Therapeutics, Inc. GBT | T. Rowe Price Associates, Inc. | 4,063,123 6.500% | -1,593,062 (-28.16%) | Filing |